PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
← catalyst calendarNCT07611214 · readout in 926 d
Sponsored by Aurinia Pharmaceuticals Inc. (industry) · AUPH — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
150estimated
Sites
27
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-22 | actual | When the study began enrolling |
| Primary completion | 2029-03-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-02 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lupus Nephritis
Interventions
- Drug: LUPKYNIS
- Biological: belimumab, obinutuzumab or anifrolumab
- Drug: mycophenolic acid analog (MPAA)
- Drug: corticosteroid
Primary outcome
what the primary-completion date above is the date OFTo assess the efficacy of LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response: Proportion of patients with complete renal response at 24 weeks
measured 24 weeks
Permalink · AUPH's whole pipeline · Catalyst calendar · Every registered study · What changed